Skip to main content

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Terminated · Phase 3 · NCT04396574

Conditions: Migraine

At a glance

Research payments reported, 2025
$730,581
U.S. investigators named
52
Sites paid
56
Planned or actual enrollment
558

About the trial

Sponsor
Eli Lilly and Company
Tested
Lasmiditan (drug)
Dates
Started 2020-06-30; completion 2025-12-04
Results posted
Yes

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.

From ClinicalTrials.gov, last updated 2026-06-25. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $730,581 in research payments for this study in 2025 (87 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Medical Research PArtners $168,183
  • Ezy Medical Research Co $39,670
  • Puerto Rico Health and Wellness Institute $38,870
  • Chicago Headache Center $34,659
  • Frontier Clinical Research LLC $29,784
  • Velocity Clinical Research Inc $29,440
  • Cincinnati Children's Hospital Medical Center, OH $28,764
  • Suncoast Clinical Research $27,056
  • Neurology Associates of Tucson $22,983
  • Elligo Health Research Inc $20,195
  • Ohsu Hospital and Clinics, OR $19,903
  • Childrens Hospital, LA $19,753
  • Clinvest Headlands LLC $19,015
  • Clinpoint Trials LLC $18,137
  • Minneapolis Clinic of Neurology $15,533
  • Integrated Clinical Trial Services Inc $13,034
  • Eastside Therapeutic Resource Inc $12,621
  • Seattle Children's Hospital, WA $12,528
  • Clinical Neuroscience Solutions DBA Cns Hlthcare $12,228
  • Hawaii PAcific Neuroscience LLC $11,653
  • Allied Physicians Inc DBA Fort Wayne Neurological Center $11,170
  • Hope L. O'brien $10,317
  • Arkansas Childrens Hospital $9,929
  • Great Lakes Research Group Inc $8,725
  • Pediatric Neurology PA $7,711
  • Yale University $7,596
  • Deaconess Clinic Inc $7,506
  • Dr Samuel Sanchez Psc $6,821
  • Rehabilitation & Neurological Services, Ll $6,783
  • Northwest Clinical Research Center $5,782
  • Qualmedica Research LLC $5,601
  • University of Kentucky Research Foundation $5,268
  • University of Miami $5,178
  • Children's Hospital Colorado, CO $4,965
  • Josephson Wallack Munshower Neurology $4,864
  • Monroe Biomedical Research $4,069
  • Alexian Brothers Hospital Network $3,500
  • Wellness Clinical Research LLC $3,416
  • Pediatrix Medical Group of Florida $2,743
  • Center for Dermatology and Plastic Surgery $2,713
  • Memorial Health Services $2,190
  • California Research Trials $2,008
  • Tribe Clinical Research LLC $1,920
  • Univ of South Florida Rsrch Foundation $1,550
  • New Horizon Research Center $1,225
  • Puerto Rico Health Institute LLC $467
  • Omega Research Consultants LLC $466
  • Deaconess Hospital Inc, IN $466
  • Central Research Associates, Inc $450
  • Sky Clinical Research Network Group $362
  • Clinvest Research LLC $251
  • Phoenix Children's Hospital, AZ $250
  • Clinedge LLC $134
  • $55
  • Scott Health Services LLC $53
  • University of Kentucky Hospital, KY $38
  • Wake Research Associ $33

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.